Bank of New York Mellon
FULC icon

Bank of New York Mellon’s Fulcrum Therapeutics FULC Stock Holding History

Bank of New York Mellon’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$566K Buy
154,513
+4,571
+3% +$27.8K ﹤0.01% 3685
2026
Q1 		$1.15M Buy
149,942
+33,036
+28% +$306K ﹤0.01% 3124
2025
Q4 		$1.32M Sell
116,906
-2,252
-2% -$22.9K ﹤0.01% 3081
2025
Q3 		$1.1M Sell
119,158
-17,842
-13% -$129K ﹤0.01% 3162
2025
Q2 		$943K Sell
137,000
-6,588
-5% -$35.2K ﹤0.01% 3157
2025
Q1 		$414K Buy
143,588
+1,715
+1% +$6.3K ﹤0.01% 3545
2024
Q4 		$667K Buy
141,873
+3,126
+2% +$11.5K ﹤0.01% 3373
2024
Q3 		$495K Sell
138,747
-47,980
-26% -$356K ﹤0.01% 3523
2024
Q2 		$1.16M Buy
+186,727
New +$1.41M ﹤0.01% 3112
2024
Q1 		– Sell
-19,831
Closed -$134K – 4215
2023
Q4 		$134K Sell
19,831
-41,359
-68% -$184K ﹤0.01% 4036
2023
Q3 		$272K Sell
61,190
-1,132
-2% -$4.95K ﹤0.01% 3851
2023
Q2 		$206K Sell
62,322
-149,879
-71% -$440K ﹤0.01% 3970
2023
Q1 		$605K Buy
212,201
+14,345
+7% +$129K ﹤0.01% 3389
2022
Q4 		$1.44M Buy
197,856
+65,383
+49% +$426K ﹤0.01% 3020
2022
Q3 		$1.07M Buy
132,473
+28,053
+27% +$201K ﹤0.01% 3174
2022
Q2 		$512K Buy
104,420
+3,781
+4% +$36.9K ﹤0.01% 3566
2022
Q1 		$2.38M Sell
100,639
-31
-0% -$439 ﹤0.01% 2832
2021
Q4 		$1.78M Buy
100,670
+5,639
+6% +$112K ﹤0.01% 3063
2021
Q3 		$2.68M Buy
95,031
+31,059
+49% +$589K ﹤0.01% 2823
2021
Q2 		$670K Buy
63,972
+21,725
+51% +$220K ﹤0.01% 3632
2021
Q1 		$497K Sell
42,247
-765
-2% -$9.46K ﹤0.01% 3692
2020
Q4 		$504K Buy
43,012
+6,457
+18% +$73K ﹤0.01% 3613
2020
Q3 		$291K Buy
36,555
+4,641
+15% +$55.9K ﹤0.01% 3731
2020
Q2 		$583K Sell
31,914
-1,389
-4% -$21.9K ﹤0.01% 3401
2020
Q1 		$398K Buy
+33,303
New +$533K ﹤0.01% 3484

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's FULC Position: Q2 2026 in Review

Bank of New York Mellon increased its Fulcrum Therapeutics (FULC) stake by 3% in Q2 2026, buying an estimated $27.8K and bringing the position to 154,513 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #3685.

Bank of New York Mellon first reported a position in FULC in Q1 2020 and has held it in 25 quarters since. The position peaked at $2.68M in Q3 2021. 50 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Bank of New York Mellon held 154,513 shares of Fulcrum Therapeutics worth $566K as of Q2 2026.
  • Bank of New York Mellon bought 4,571 Fulcrum Therapeutics shares in Q2 2026, an estimated $27.8K.
  • Fulcrum Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3685 holding.
  • Bank of New York Mellon first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Bank of New York Mellon's Fulcrum Therapeutics position peaked at $2.68M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.